Posts by Hemlata
DISTILL by SVMPharma designed and developed by researchers for clinical research organisations
DISTILL is designed from the ground up to allow sponsors to self-configure and run clinical trials, however at SVMPharma our product specialists are ready to assist at any stage. Our agile approach ensures rapid, fully tested trial setup and in-study changes. Combined with DISTILL’s low-code, no-code platform, we are able to offer quicker user acceptance…
Read MoreReal-world data as an evidence source in nuclear medicine
RWE use is becoming particularly relevant in oncology, as only a small percentage of adult cancer patients worldwide are enrolled in clinical trials whereas the number of therapeutic options and the segmentation of patient populations are rapidly increasing, leading to the explosive growth of research questions and evidence gaps High-quality RWE from electronic health records…
Read MoreDISTILL from SVMPharma, a new electronic data capture system
DISTILL is designed from the ground up to allow sponsors to self-configure and run clinical trials, however at SVMPharma our product specialists are ready to assist at any stage. Our agile approach ensures rapid, fully tested trial setup and in-study changes. Combined with DISTILL’s low-code, no-code platform, we are able to offer quicker user acceptance…
Read MoreIndustry leaders praise real-world evidence (RWE) in COVID-19 pandemic
Scott Gottlieb, Former Commissioner of the FDA has pointed out several ways RWE has been utilised during the COVID-19 pandemic: Post-market data collection: RWE will provide flexibility for post-market safety and effectiveness data collection on the initial cohorts of patients Regulatory decision making: RWE has been an important factor in making decisions about patient care…
Read MoreWhy was DISTILL built on Low-Code, No-Code?
DISTILL is designed from the ground up to allow sponsors to self-configure and run clinical trials, however at SVMPharma our product specialists are ready to assist at any stage. Our agile approach ensures rapid, fully tested trial setup and in-study changes. Combined with DISTILL’s low-code, no-code platform, we are able to offer quicker user acceptance…
Read MoreArtificial intelligence (AI) is revolutionising healthcare services
AI may improve clinical research through its ability to better translate RWD into RWE, thus providing more valid evidence of clinical benefits and risks AI is poised to transform the drug and device development process, helping researchers refine the approval process and significantly cutting both the time and the expense needed to bring products to…
Read MoreDISTILL meeting your clinical trial requirements
DISTILL is designed from the ground up to allow sponsors to self-configure and run clinical trials, however at SVMPharma our product specialists are ready to assist at any stage. Our agile approach ensures rapid, fully tested trial setup and in-study changes. Combined with DISTILL’s low-code, no-code platform, we are able to offer quicker user acceptance…
Read MoreVerantos announces breakthrough in non-alcoholic steatohepatitis real-world evidence
In an observational analysis, traditional approaches resulted in data accuracy of 54.1%; using advanced approaches, however, including unstructured data, natural language processing, and artificial intelligence-based inference, Verantos, Amgen, and Virginia Commonwealth University researchers achieved 78% improved data accuracy According to the American Liver Foundation, 25% of Americans have non-alcoholic fatty liver disease (NAFLD) or NASH,…
Read MoreDISTILL by SVMPharma, designed and developed by researchers for clinical research organisations
DISTILL is designed from the ground up to allow sponsors to self-configure and run clinical trials, however at SVMPharma our product specialists are ready to assist at any stage. Our agile approach ensures rapid, fully tested trial setup and in-study changes. Combined with DISTILL’s low-code, no-code platform, we are able to offer quicker user acceptance…
Read MoreNew tools and methods are empowering both patients and providers to make an effective choice of asthma treatment
The decision and conversation aid for mild asthma were developed through a scientific process and through engagement with asthma patients and primary care providers, and in accordance with all qualifying and certifying criteria The goal of these newly developed tools is to help patients and providers to achieve that “shared decision making” in real practice…
Read More